argenx to Present at Upcoming Investor Conferences
February 27, 2023 - argenx (Euronext & Nasdaq: ARGX), an immunology company, announced participation in key investor conferences in March.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
February 27, 2023 - argenx (Euronext & Nasdaq: ARGX), an immunology company, announced participation in key investor conferences in March. The Cowen 43rd Annual Healthcare Conference will feature a fireside chat on March 6, 2023, at 10:30 a.m. ET in Boston, MA. Additionally, the Raymond James 44th Annual Institutional Investors Conference will host a presentation on March 7, 2023, at 1:05 p.m. ET in Orlando, FL.
Investors can find more details on the argenx website.
Details
News Market Reaction – ARGX
The recorded move for ARGX in the trading session of this news was +1.00%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
February 27, 2023
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in several upcoming investor conferences in March:
- Cowen 43rd Annual Healthcare Conference. Fireside chat on Monday, March 6, 2023 at 10:30 a.m. ET in Boston, MA.
- Raymond James 44th Annual Institutional Investors Conference. Presentation on Tuesday, March 7, 2023 at 1:05 p.m. ET in Orlando, FL.
Additional information regarding these events will be available on the Investors section of the argenx website at argenx.com/investors.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S., the EU and Japan. For more information, visit www.argenx.com and follow us on LinkedIn, Twitter, and Instagram.
For further information, please contact:
Media:
Kelsey Kirk
kkirk@argenx.com
Investors:
Beth DelGiacco
bdelgiacco@argenx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.